RPG Life Sciences Limited Stock Bombay S.E.

Equities

RPGLIFE

INE105J01010

Pharmaceuticals

Delayed Bombay S.E. 12:43:33 2024-04-25 am EDT 5-day change 1st Jan Change
1,550 INR +0.37% Intraday chart for RPG Life Sciences Limited +2.39% +15.97%
Sales 2022 4.4B 52.79M Sales 2023 5.13B 61.51M Capitalization 11.58B 139M
Net income 2022 515M 6.18M Net income 2023 676M 8.11M EV / Sales 2022 1.98 x
Net cash position 2022 560M 6.72M Net cash position 2023 832M 9.98M EV / Sales 2023 2.1 x
P/E ratio 2022
18 x
P/E ratio 2023
17.1 x
Employees 1,214
Yield 2022
1.71%
Yield 2023
1.71%
Free-Float 29.34%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.37%
1 week+2.39%
Current month+1.29%
1 month+3.74%
3 months-3.74%
6 months+13.66%
Current year+15.97%
More quotes
1 week
1 481.30
Extreme 1481.3
1 560.00
1 month
1 458.95
Extreme 1458.95
1 622.55
Current year
1 325.00
Extreme 1325
1 740.00
1 year
745.00
Extreme 745
1 740.00
3 years
422.00
Extreme 422
1 740.00
5 years
146.00
Extreme 146
1 740.00
10 years
65.00
Extreme 65
1 740.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 15-12-31
Director of Finance/CFO - 20-08-02
Compliance Officer - 11-11-10
Members of the board TitleAgeSince
Chairman 66 08-02-05
Director/Board Member 83 08-02-05
Director/Board Member 60 08-02-05
More insiders
Date Price Change Volume
24-04-25 1,550 +0.37% 134
24-04-24 1,544 -0.03% 962
24-04-23 1,545 +1.36% 738
24-04-22 1,524 +2.30% 472
24-04-19 1,490 -1.59% 1,917

Delayed Quote Bombay S.E., April 25, 2024 at 12:43 am EDT

More quotes
RPG Life Sciences Limited is an India-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas, including nephrology, oncology, rheumatology, cardiology, respiratory, nutritional, gastroenterology, and diabetology, among others. The international formulations business is involved in developing, manufacturing and marketing oral solid formulations in the generic and branded generic space across regulated and emerging markets. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Sodium Valproate PR, Nicorandil, Quinfamide, Nicorandil, Haloperidol, Risperidone, and others.
More about the company

Annual profits - Rate of surprise